PeptiDream: long-term performance & turning pointsSales (revenue) and profit-margin ratio
Sales (¥ bn)Net margin (%)
2006A laboratory technique made into a platform
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
2006Founded in Tokyo by Suga Hiroaki and Kubota Kiichi
2006Exclusive flexizyme licence from the University of Tokyo
2010PDPS drug-discovery platform established
PeptiDream was founded in Chiyoda, Tokyo, in July 2006 by two men with deliberately separated jobs. Suga Hiroaki, then a professor at the University of Tokyo’s Research Center for Advanced Science and Technology, had developed flexizyme — an artificial RNA catalyst that lets unnatural amino acids be loaded into a peptide chain, and so lets vast libraries of macrocyclic peptides be built and screened. Kubota Kiichi, who had come through Nissan Motor and the drug-discovery firm JGS, took the business. The split was the point: Kubota held that when the same person runs the research and the company, the inventor’s science bends to commercial judgement. Suga stayed with the technique and its publication; Kubota decided what the company would and would not do.
The founding asset was a licence rather than a laboratory. In December 2006 the company took an exclusive licence with sublicensing rights to the flexizyme patents from the University of Tokyo, and in May 2007 the same from the State University of New York. Offices moved to Meguro in 2009 and the laboratories were consolidated into the university’s Komaba Research Campus in April 2010.
In October 2010 PeptiDream announced the Peptide Discovery Platform System (PDPS), which uses flexizyme to narrow drug candidates out of libraries on the order of a quadrillion cyclic peptides. With it came the choice that defined the company. Developing a drug end to end means years without revenue and only one or two programmes at a time; instead PeptiDream would find candidates and hand everything downstream — target selection, trials, marketing — to the pharmaceutical companies, earning upfront payments, milestones and royalties. It never sold a drug. It rented the machine that finds them.
PeptiDream listed on the Tokyo Stock Exchange’s Mothers market in June 2013, seven years after it was founded and — unusually for a Japanese biotech — already profitable. Revenue in the year to June 2014 was about $7.6M (¥800m), small in absolute terms but earned rather than raised. In the seven years to listing the company had signed licence and joint-research agreements in quick succession with Takeda Pharmaceutical, Astellas Pharma, Bristol Myers Squibb and Novartis; contract research fees, not investor money, were the pillar of its accounts.
The market rewarded it quickly. In December 2015 the shares moved from Mothers to the First Section of the Tokyo Stock Exchange, with revenue reaching roughly $39.5M (¥4bn) in the year to June 2016 — a promotion nine years after founding, an exceptional pace for a university spinout in a sector where a decade of losses is the norm.
2017A scientist president, and the ventures around the platform
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
FY2017 · unconsolidated
Revenue$44M
Net income$17M
Net margin38.8%
→
FY2021 · consolidated
Revenue$86M
Net income$24M
Net margin27.7%
2017Head office moves to Kawasaki; Patrick Reid becomes president
2017Peptistar founded with Shionogi and Sekisui Chemical
2019Fiscal year end changed from June to December
2020PeptiGrowth (with Mitsubishi Corp.) and PeptiAid founded
The founders began to withdraw. Kubota became chairman in 2016, and in September 2017 Patrick Reid — an American researcher who had built out the PDPS technology as chief science officer, by way of Dartmouth Medical School, Kobe University and US discovery groups — became president. Putting a bench scientist rather than a businessman in the chair served two ends at once: it pushed the international licensing effort, and it settled the succession beyond the two founders.
The same year the company moved its head office and laboratories to the Kingskyfront district of Kawasaki, and in September 2017 set up Peptistar, a contract manufacturer of special peptide active ingredients jointly owned with Shionogi and Sekisui Chemical. It was a characteristic move: the downstream gap was real, but the plant was placed in a separate company with other people’s capital in it, so that PeptiDream itself stayed light.
More partnerships followed the same shape. The fiscal year end was moved from June to December in 2019, leaving a six-month transitional period, to fall in line with the international partners whose contracts now drove the accounts. In April 2020 PeptiDream formed PeptiGrowth with Mitsubishi Corporation for cell-culture media peptides, and in November 2020 PeptiAid with Fujitsu, Mizuho Capital, Takenaka and Kishida Chemical to pursue a COVID-19 therapy. Revenue reached about $109.6M (¥12bn) in 2020 on an operating margin close to 60%.
2021Agrees to acquire PDR Pharma from Fujifilm Toyama Chemical
2022PDR Pharma consolidated; listing moves to the Prime Market
2024Consolidated revenue reaches $308.3M (¥47bn)
2025Revenue falls back; first operating loss since listing
In September 2021 PeptiDream agreed to buy PDR Pharma, the radiopharmaceutical business of Fujifilm Toyama Chemical, for about $277.8M (¥31bn); the price was cut to roughly $168.2M (¥22bn) when sales rights were returned before the deal closed in March 2022. In April the listing moved to the new Prime Market. For the first time the company owned manufacturing and marketing approvals — it sold products, to patients, under its own name.
The scale changed at once. Consolidated revenue went from about $85.6M (¥9bn) in 2021 to $204.8M (¥27bn), then $308.3M (¥47bn) in 2024 as PDR Pharma’s actual sales carried the group. But the second pillar brought goodwill and intangible amortisation with it, and in 2025 revenue fell back to roughly $123.6M (¥19bn) and operating results turned to a loss — the discovery business is lumpy by nature, since a contract signed or a milestone reached lands in one year and not the next.
Both founders have stepped back: Suga remains a professor at the University of Tokyo and an adviser to the company, and Kubota has left the front line. Reid runs the company with externally recruited finance and operating executives. What remains from 2006 is the flexizyme licence — but it is now one of two businesses rather than the whole of one, which is what the acquisition was for.
A business designed to be profitable — and what that cost it as a drug company
The core of this decision was that PeptiDream refused the biotech orthodoxy of the day — run the research on outside money and treat losses as a given — and instead assembled in advance a business model in which a profitable, independently run company was possible. To aim at being a “mini pharma” selling its own drugs would have meant being pulled forever between the demands of maintaining a listing and the demands of research. Kubota Kiichi was able to choose, and hold to, a design of supplying technology to the majors while running many programmes in parallel because two things overlapped: exclusive access to Suga Hiroaki’s technology, and a structure that kept invention and management apart. That is also why the listing could be a place to present the model rather than to raise money.
Even so, the reliance on partnership that made profit possible was, turned around, a handing of the initiative in creating new drugs to the other side. With the market waiting on the few new drugs that appear in any year, the limit of the model can be seen in the fact that Kubota himself acknowledged the fading of the company’s brand and called its market capitalisation a matter of “expectation.” A design that stayed profitable on its own did not amount to completion as a drug company. On the partnership-shaped frame that set within a few years of listing, the question of how to stack up results of its own was carried over to the management that succeeded him.
What it means for a discovery company to take on manufacturing
The heart of this decision was that it carved out manufacturing alone — the heavy step — into a separate company, without breaking the light structure of a discovery-only business. However fast PDPS finds candidates, there is no medicine unless the active ingredient can be produced at stable volume. To keep the nimbleness of holding neither plant nor inventory while closing the narrow point downstream, sharing capital in a joint venture with Shionogi and Sekisui Chemical, who had the technology, made more sense than owning a factory outright. The care in the design shows in the refusal to house discovery and manufacturing under one roof, placing them instead in separate legal entities.
That said, the joint-venture form, while sparing PeptiDream from carrying the difficulty of manufacturing alone, also left a structure in which it could not decide the success of scale-up by itself. The cost of making special peptides remained high even after the plant was running, and the original problem — establishing mass-production technology — was carried forward for years. That the venture required funding on the order of $181.2M (¥20bn) and several shareholders is itself a sign that bringing manufacturing in-house held a difficulty of a different order from discovery. Whether the standing PeptiDream earned in discovery can be carried through to practical medicines depends on how far this joint venture can lower the wall of mass production.
To read this acquisition only as a highly profitable venture comfortably buying itself a second pillar is to make the state of the business too simple. PeptiDream’s founding trade — joint research and technology licensing — carried very high margins, as an operating margin of 59% shows, but it rested on partnerships and contract work with others and lacked any product the company manufactured and sold itself. That it took in radiopharmaceuticals together with their manufacturing and marketing base, at a time when announcing new partnerships had stopped moving the share price, suggests an intent to break out of dependence on a single platform.
Even so, gaining a second pillar did not in itself bring stability. Just before completion the consideration was cut from $277.8M (¥31bn) to $168.2M (¥22bn) when sales rights were returned, and the radiopharmaceutical business that widened the consolidated scale at a stroke brought with it the weight of goodwill and intangible-asset amortisation. That revenue shrank and operating results turned to a loss in the year to December 2025 shows that a decision to rebuild the business on two pillars brings scale and volatility of earnings bundled together. How to mesh a manufacturing-and-marketing business of an entirely different nature with the high profitability of the founding trade is the problem left over once the acquisition was done.
Each heading links to the full Japanese analysis — background, decision and outcome, with sources.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— PeptiDream full history in Japanese →
PeptiDream Inc. — 有価証券報告書 (annual securities reports) and news releases.
Weekly Toyo Keizai — 週刊東洋経済, 29 Dec 2018: interview with chairman Kubota Kiichi, “Building a business model investors can accept.” Toyo Keizai DCL.
Weekly Toyo Keizai — 週刊東洋経済, 17 Apr 2021: “PeptiDream’s advance — the star with a 59% operating margin.” Toyo Keizai DCL.
Toyo Keizai Online — 東洋経済オンライン, 17 Jan 2020: Kubota Kiichi and Suga Hiroaki on entrepreneurship.
Nihon Keizai Shimbun — 日本経済新聞: 1 Jun 2017 (Peptistar); 18 Apr 2018 (Peptistar raises about $181.2M (¥20bn)); 2 Sep 2021 (the Fujifilm radiopharmaceutical acquisition).
This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
Company names, logos and other marks belong to their respective owners.
Data API
PeptiDream’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.